Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05090345 · ClinicalTrials.gov registry record
A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
A clinical trial of Hematopoietic Cell Transplantation, sponsored by Duke University.
- Recruiting
- Registry status
- 500
- Enrollment target
- 3
- Study locations
NCT05090345: Recruiting study of Hematopoietic Cell Transplantation, sponsored by Duke University.
NCT05090345 is a study of Hematopoietic Cell Transplantation that is actively recruiting participants, run by Duke University. The registered enrollment target is 500 participants, above the 115-participant average among 4 other Hematopoietic Cell Transplantation trials with a reported enrollment target (335% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05090345, a study of Hematopoietic Cell Transplantation, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
Conditions Studied
Interventions
- OTHER Biorepository Trial
Study Locations (3)
Minnesota
- Mayo Clinic - Rochester
North Carolina
- Duke University - Durham
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2026-02-05 |
What NCT05090345 shows while recruiting
NCT05090345 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 4 other Hematopoietic Cell Transplantation trials with a reported enrollment target (335% higher).
The record links to 1 condition, with Hematopoietic Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Biorepository Trial is the first listed.
NCT05090345 reports a single indexed study location in Minnesota, North Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT05090345 about?
NCT05090345 is a clinical study titled "A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).". This is a prospective international multi-center registry and biorepository trial of children and adolescents/young adults (AYA) undergoing hematopoietic cell transplantation (HCT) to assess the impact of endotheliopathies in the HCT setting as a contributor of significant morbidity and mortality.
What is the current status of trial NCT05090345?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-11-19. Estimated completion is 2026-02-05.
What conditions does trial NCT05090345 study?
This clinical trial studies the following conditions: Hematopoietic Cell Transplantation.
What interventions are being tested in trial NCT05090345?
The interventions under investigation include: Biorepository Trial (OTHER).
Who is sponsoring clinical trial NCT05090345?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05090345 being conducted?
This trial has 3 study locations across Minnesota, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
RECRUITING
-
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
RECRUITING · Phase 1
-
Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.
ACTIVE NOT RECRUITING
-
FMT In High-Risk Acute GVHD After ALLO HCT
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI